Login to Your Account



Qsymia Uptake Slow, Steady, but Will It Win Obesity Race?

By Catherine Shaffer
Staff Writer

Tuesday, October 23, 2012

Four weeks after its launch, 2,000 patients were taking obesity drug Qsymia (phentermine/topiramate), from Vivus Inc., with new patient starts slowing from an initial four- or fivefold increase to a 27 percent to 33 percent increase from week three to week four, according to IMS and Wolters Kluwer weekly prescription data.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription